TB is preventable and treatable, and the world has set the objective of ending the disease by 2030. TB preventive treatment is one of the best ways to keep individuals and families safe from TB, which in turn helps communities become—and remain—TB free. Read more in this report.
The goal of these materials is to teach patients about TB infection and to motivate them to start and complete treatment if diagnosed. The materials are designed to encourage provider-patient interactions for active learning through the process of testing and treatment decisions. There are four materials in this series and it is suggested to use the materials as a continuum, as they build upon each other.
This booklet provides information on the diagnosis and treatment of TB infection and TB disease. Key audiences for this resource are people with or at risk for TB; people who may have been exposed to someone with TB; people who provide services for those at high risk for TB, such as correctional officers, homeless shelter workers, and emergency responders; and people who want to learn more about tuberculosis.
Tuberculosis (TB) is one of the world’s leading infectious disease killers, and it is both contagious and deadly. Up to 13 million people are living with latent tuberculosis infection in the United States. Without treatment, 5-10% will develop into TB disease. Yet, the notion that TB is no longer a...
This material was developed for clinicians to use with patients that are prescribed the three months of daily isoniazid plus rifampin (3HR) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 3HR regimen.
This material was developed for clinicians to use with patients that are prescribed the four months daily rifampin (4R) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 4R regimen.
This material was developed for clinicians to use with patients that are prescribed the 12-dose regimen for the treatment of latent TB infection. There is space to write treatment schedules, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 12-dose regimen.
The patient education brochure was developed for clinicians to use with patients while discussing the 12-dose regimen for the treatment of latent TB infection. The brochure contains information on latent TB infection, the 12-dose regimen, and adverse events.
The handout describes the main characteristics of LTBI and Active TB, as well as their differences. The material also describes what increases the risk for developing Active TB and how to prevent TB from developing. English is on one side and Mandarin is on the other.
This material was developed for clinicians to use with patients that are prescribed the four months daily rifampin (4R) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 4R regimen.
